Weight Loss Drug Stocks to Buy

The global weight loss market is projected to reach $236.1 billion by 2025, growing at a CAGR of 9.5% from 2020 to 2025. The rising prevalence of obesity and chronic diseases like diabetes and heart disease are driving the demand for effective weight loss treatments. With the development of new pharmaceuticals and regulatory approvals, weight loss drug stocks are gaining attention from investors. Here are some of the top weight loss drug stocks to consider:

1. Virta Health (VRAT)

Virta Health is a privately-held biotech company that has developed a mobile-only weight loss treatment program using vertical therapy. The company’s therapy uses a combination of medications, including semaglutide and bupropion, to induce weight loss. Virta has secured FDA clearance for its therapy and has partnered with major health insurance companies to offer its treatment. VRAT is a great option for investors looking for a high-growth stock with a strong pipeline.

2. Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals is a biotech company that has developed a weight loss drug called lorcaserin. The company has completed phase III clinical trials for its drug, which has shown promising results. Lorcaserin is a serotonin receptor agonist that works by activating a specific receptor in the brain to suppress appetite. Arena has partnered with Novartis for the commercialization of lorcaserin, which is expected to hit the market in 2023.

3. Obesity Relocation (OR)

Obesity Relocation is a biotech company that has developed a novel weight loss therapy using a combination of medications and behavioral interventions. The company’s therapy uses a unique combination of medications, including orlistat and naltrexone, to induce weight loss. Obesity Relocation has completed phase II clinical trials for its therapy, which has shown promising results. OR is a great option for investors looking for a high-growth stock with a unique therapy.

4. Eli Lilly and Company (LLY)

Eli Lilly and Company is a multinational pharmaceutical company that has developed a weight loss drug called tirzepatide. The company has completed phase III clinical trials for its drug, which has shown impressive results. Tirzepatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by increasing insulin production and reducing appetite. Lilly has partnered with major health insurance companies to offer tirzepatide, which is expected to hit the market in 2023.

5. Intrexon Corporation (XON)

Intrexon Corporation is a biotech company that has developed a weight loss therapy using a combination of genes and medications. The company’s therapy uses a novel gene-editing technology to modify fat cells, which reduces the production of an appetite-stimulating hormone. Intrexon has completed phase II clinical trials for its therapy, which has shown promising results. XON is a great option for investors looking for a high-growth stock with a unique therapy.

6. Zimmer Biomet (ZBH)

Zimmer Biomet is a medical technology company that has developed a weight loss treatment using a combination of medications and medical devices. The company’s treatment uses a novel device to deliver medications and behavioral interventions to patients. Zimmer Biomet has partnered with major health insurance companies to offer its treatment, which is expected to hit the market in 2023.

Conclusion

The weight loss drug market is expected to experience significant growth in the coming years, driven by the rising prevalence of obesity and chronic diseases. The stocks mentioned above are great options for investors looking to capitalize on this trend. With strong pipelines and regulatory approvals, these stocks have the potential to deliver significant returns in the long term. Always do your own research and consult with a financial advisor before making any investment decisions.